Elicio Therapeutics (ELTX) Gains from Investment Securities (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Gains from Investment Securities data on file, last reported at $984000.0 in Q1 2026.

• Quarterly Gains from Investment Securities rose 94.08% year-over-year to $984000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 23.21% YoY) and the FY2025 annual result came in at $1.9 million, down 50.72% from the prior year.
• Gains from Investment Securities improved to $984000.0 in Q1 2026, from -$1.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $5.6 million in Q3 2024 to a low of -$3.6 million in Q2 2024.
• A 5-year average of $484785.7 and a median of $273000.0 in 2022 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 93716.67% in 2024, down 15821.74% in 2024.
• Tracing ELTX's Gains from Investment Securities over 5 years: stood at $39000.0 in 2022, then sank by 138.46% to -$15000.0 in 2023, then surged by 4146.67% to $607000.0 in 2024, then plunged by 307.91% to -$1.3 million in 2025, then surged by 177.97% to $984000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $984000.0 (Q1 2026), -$1.3 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.